Skip to main content
Clinical Trials/NCT01074164
NCT01074164
Completed
Not Applicable

Evaluating the Effectiveness of Acupressure in Relieving Pruritus Related to Atopic Dermatitis

Northwestern University1 site in 1 country15 target enrollmentFebruary 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atopic Dermatitis
Sponsor
Northwestern University
Enrollment
15
Locations
1
Primary Endpoint
Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to see if acupressure will be effective at reducing itch in people with atopic dermatitis (AD).

Detailed Description

Atopic dermatitis (AD) is recognized as a major and common problem worldwide. In the United States, AD and related eczematous symptoms affect 17% of the population; 1 in 10 individuals report having experienced symptoms causing quality of life (QOL) distress, including itching/scratching, red/inflamed rash, excessive dryness/scaling, and/or symptoms lasting ≥ 14 days. Two-thirds of these subjects noted at least moderate to severe symptoms, with itch being the most disturbing. Effective treatment of AD and of pruritus (itching) are interconnected. Treating AD will decrease the stimulus for the itch, whereas treating pruritus will decrease the feedback cycle brought on when a patient scratches the skin continually. Effective medications for AD and related symptoms include topical corticosteroids and calcineurin inhibitors. Oftentimes, these remedies are insufficient at treating the itch component of the disease. There is demand for alternative, complementary treatments for AD-related pruritus.

Registry
clinicaltrials.gov
Start Date
February 2010
End Date
December 2010
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dennis West

Professor of Dermatology and Pediatrics

Northwestern University

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of AD by dermatologist
  • Not currently using acupressure or acupuncture for treatment of AD
  • Able to read, write, and understand study materials
  • Age 18 or older

Exclusion Criteria

  • Unable to physically perform acupressure technique
  • Significant comorbidities causing itch such as chronic urticaria, renal failure, notalgia paresthetica, and tinea

Outcomes

Primary Outcomes

Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score

Time Frame: Baseline and 4 weeks

The VAS score assesses itch intensity in subject's with AD. The VAS consists of a 21.5 cm horizontal line with its left and right boundaries marked by vertical lines. The left boundary vertical line is labeled "Least Itch," and the right boundary vertical line is labeled "Worst Itch." Subjects are instructed to draw a vertical line across this scale that represents the intensity of itch that they are currently experiencing. Vertical lines drawn by subjects towards the left boundary of the horizontal line are associated with less itch intensity, and vertical lines drawn by subjects towards the right boundary of the horizontal line are associated with worse itch intensity. A ruler is then used to measure distance from the left boundary vertical line to the vertical line drawn by the subject to the nearest millimeter. Possible values range from 0 to 21.5 centimeters, with 0 centimeters associated with less itch intensity and 21.5 cm associated with worse itch intensity.

Secondary Outcomes

  • Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Investigator Global Assessment (IGA) Score(Baseline and 4 weeks)
  • Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Eczema Area and Severity Index (EASI): Area Subscale Score(Baseline and 4 weeks)
  • Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Eczema Area and Severity Index (EASI): Erythema Subscale Score(Baseline and 4 weeks)
  • Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Eczema Area and Severity Index (EASI): Infiltration/Papulation Subscale Score(Baseline and 4 weeks)
  • Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Eczema Area and Severity Index (EASI): Excoriation Subscale Score(Baseline and 4 weeks)
  • Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Eczema Area and Severity Index (EASI): Lichenification Subscale Score(Baseline and 4 weeks)

Study Sites (1)

Loading locations...

Similar Trials